Shares of hVIVO plc (LON:HVO - Get Free Report) were down 44.5% during trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 9 ($0.12). Approximately 79,187,813 shares were traded during trading, an increase of 2,238% from the average daily volume of 3,386,995 shares. The stock had previously closed at GBX 16.20 ($0.22).
Wall Street Analyst Weigh In
Separately, Shore Capital reiterated a "buy" rating on shares of hVIVO in a research note on Friday.
Check Out Our Latest Analysis on hVIVO
hVIVO Stock Down 46.3%
The firm's 50 day simple moving average is GBX 16.16 and its 200-day simple moving average is GBX 18.13. The company has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.
hVIVO (LON:HVO - Get Free Report) last posted its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, sell-side analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.
Insiders Place Their Bets
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($700,459.93). 14.03% of the stock is currently owned by corporate insiders.
About hVIVO
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
